A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback